Effects of fludarabine treatment on murine lupus nephritis

Lupus

Volumn 13, Issue 12, 2004, Pages 912-916

  Jones, Olcay Y ^a,d   Alexander, P J ^a   Lacson, A ^b   Gok, F ^c   Feliz, A ^a   Marikar, Y ^a   Madivi, C ^a   Jones, J M ^a   Good, R A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cyclophosphamide; Fludarabine; Lupus; Mouse; Nephritis

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; FLUDARABINE; INTERLEUKIN 2 RECEPTOR; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; HISTOPATHOLOGY; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RAT; SPLEEN CELL; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

ANIMALS; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; IMMUNOSUPPRESSIVE AGENTS; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; LYMPHOCYTE COUNT; MALE; MICE; SPLEEN; VIDARABINE;

EID: 10844228157     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu2032oa     Document Type: Article

References (21)

1. Austin HA, Balow JE. Treatment of lupus nephritis. Semin Nephrol 2000; 20: 265-276.
2. Balow JE, Austin HA. III Progress in the treatment of proliferative lupus nephritis. Curr Opin Nephrol Hypertens 2000; 9: 107-115.
3. Illei GG, Czirjak L. Novel approaches in the treatment of lupus nephritis. Expert Opin Investig Drugs 2001; 10: 1117-1130.
4. Boumpas DT, Tassiulas IO, Fleisher TA et al. A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin Nephrol 1999; 52: 67-75.
5. Keating MJ, O'Brien S, McLaughlin P et al. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther 1996; 38 (Suppl. 2) S83-91.
6. O'Brien S, Kantarjian H, Keating MJ. Purine analogs in chronic lymphocytic leukemia and Waldenstrom's macroglobulinemia. Ann Oncol 1996; 7 (Suppl. 6): S27-33.
7. Plunkett W, Gandhi V, Huang P et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993; 20: 2-12.
8. Schiavone EM, De Simone M, Palmieri S et al. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. Eur J Haematol 2003; 71: 23-28.
9. Nagler A, Aker M, Or R et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 2001; 29: 362-370.
10. Champlin R, Khouri I, Anderlini P et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Huntingt) 2003; 17: 94-100; discussion 103-107.
11. Wu T, Levay-Young B, Heuss N et al. Inducing tolerance to mhc-matched allogeneic islet grafts in diabetic nod mice by simultaneous islet and bone marrow transplantation under nonirradiative and non-myeloablative conditioning therapy. Transplantation 2002; 74: 22-27.
12. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-2448.
13. Dighiero G. Adverse and beneficial immunological effects of purine nucleoside analogues. Hematol Cell Ther 1996; 38 (Suppl. 2): S57-81.
14. Viallard JF, Mercie P, Faure I, Pellegrin JL, Leng B. Successful treatment of lupus with fludarabine. Lupus 1999; 8: 767-769.
15. Wang B, Yamamoto Y, El-Badri NS, Good RA. Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in bxsb recipient mice. Proc Natl Acad Sci USA 1999; 96: 3012-3016.
16. Petras MJ, Williams JF, Eckhaus MA, Gress RE, Fowler DH. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully mhc-mismatched murine marrow graft rejection independent of gvhd. Biol Blood Marrow Transplant 2000; 6: 182-189.
17. Sakic B, Szechtman H, Denburg SD, Denburg JA. Immunosuppressive treatment prevents behavioral deficit in autoimmune mrl-lpr mice. Physiol Behav 1995; 58: 797-802.
18. Austin HA, Patel AD, Cadena CA, Boumpas DT, Balow JE. Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus. J Rheumatol 1997; 24: 61-68.
19. Leach M, Parsons RM, Reilly JT, Winfield DA. Autoimmune thrombocytopenia: A complication of fludarabine therapy in lymphoproliferative disorders. Clin Lab Haematol 2000; 22: 175-178.
20. Jacob CO, Zang S, Li L et al. Pivotal role of stat4 and stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol 2003; 171: 1564-1571.
21. Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nature Med 1999; 5: 444-447.